CH \$290.00 450819

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM497389

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Aegerion Pharmaceuticals, Inc.		11/08/2018	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Cantor Fitzgerald Securities, as Administrative Agent
Street Address:	110 East 59th Street
City:	New York
State/Country:	NEW YORK
Postal Code:	10022
Entity Type:	General Partnership: NEW YORK

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Registration Number:	4508190	JUXTAPID
Registration Number:	4512713	JUXTAPID
Registration Number:	5276666	LOWER
Registration Number:	4589120	MYALEPT
Registration Number:	4607022	MYALEPT
Registration Number:	5237691	BYMYSIDE
Registration Number:	5237690	BYMYSIDE
Registration Number:	5381456	NOVELION THERAPEUTICS
Registration Number:	5381517	NOVELION THERAPEUTICS
Registration Number:	3300046	AEGERION
Registration Number:	3977343	AEGERION PHARMACEUTICALS

CORRESPONDENCE DATA

Fax Number: 3129939767

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3129932647

Email: zeynep.gieseke@lw.com

Correspondent Name: Zeynep Gieseke

Address Line 1: 330 North Wabash Avenue, Suite 2800

TRADEMARK REEL: 006478 FRAME: 0177

900473315

	atham & Watkins LLP Chicago, ILLINOIS 60611
ATTORNEY DOCKET NUMBER:	062219-0000
NAME OF SUBMITTER:	Zeynep Gieseke
SIGNATURE:	/zg/
DATE SIGNED:	11/08/2018
Total Attachments: 5	
source=Trademark Security Agreem	nent#page1.tif
source=Trademark Security Agreem	nent#page2.tif
source=Trademark Security Agreem	nent#page3.tif
source=Trademark Security Agreem	nent#page4.tif

source=Trademark Security Agreement#page5.tif

TRADEMARK REEL: 006478 FRAME: 0178

TRADEMARK SECURITY AGREEMENT dated as of November 8, 2018 (this "<u>Agreement</u>"), among AEGERION PHARMACEUTICALS, INC. (the "<u>Pledgor</u>") and CANTOR FITZGERALD SECURITIES, as Administrative Agent (in such capacity, the "<u>Administrative Agent</u>").

Reference is made to the Guarantee and Collateral Agreement dated as of November 8, 2018 (the "Collateral Agreement"), among AEGERION PHARMACEUTICALS, INC., a Delaware corporation, each other Subsidiary Loan Party party thereto and the Administrative Agent, pursuant to which the Pledgor granted to the Administrative Agent, for the benefit of the Secured Parties, a security interest in the Trademark Collateral (as defined herein). Pursuant to the Collateral Agreement, the Pledgor agreed to execute and deliver this Agreement in order to record the security interest granted to the Administrative Agent with the USPTO. Accordingly, the parties hereto agree as follows:

SECTION 1. <u>Terms</u>. Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified (including specified by reference) in the Collateral Agreement. The rules of construction specified in Section 1.01(b) of the Collateral Agreement also apply to this Agreement.

SECTION 2. Grant of Security Interest. As security for the payment or performance, as the case may be, in full of the Secured Obligations, the Pledgor hereby grants to the Administrative Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest (the "Security Interest") in all of such Pledgor's right, title and interest in, to and under the United States Trademark registrations and Trademark applications listed on Schedule I attached hereto, but excluding any intent-to-use Trademark application prior to the filing of a "Statement of Use" or "Amendment to Allege to Use" with respect thereto, together with (a) all renewals or extensions thereof, (b) the right to sue or otherwise recover for any past, present and future infringement, dilution, misappropriation, or other violation or impairment thereof, and (c) all Proceeds of the foregoing, including without limitation license fees, royalties, income, payments, claims, damages and proceeds of suit, now or hereafter due and/or payable with respect thereto (the "Trademark Collateral"). This Agreement is not to be construed as an assignment of any Trademark Collateral.

SECTION 3. <u>Collateral Agreement</u>. The Security Interest granted to the Administrative Agent herein is granted in furtherance, and not in limitation, of the security interests granted to the Administrative Agent pursuant to the Collateral Agreement. The Pledgor hereby acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the Trademark Collateral are more fully set forth in the Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Collateral Agreement, the terms of the Collateral Agreement shall govern.

SECTION 4. <u>Termination</u>. Upon the occurrence of the Termination Date or the release of the Pledgor from its obligations under the Collateral Agreement pursuant to Section 7.15 of the Collateral Agreement, the security interest granted herein shall automatically terminate and the Administrative Agent shall execute, acknowledge, and deliver to the Pledgor

TRADEMARK REEL: 006478 FRAME: 0179 an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien, and security interest in the Trademark Collateral under this Agreement.

SECTION 5. <u>Counterparts</u>. This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original but all of which when taken together shall constitute a single contract. Delivery of an executed signature page to this Agreement by facsimile or other electronic transmission shall be effective as delivery of a manually signed counterpart of this Agreement.

SECTION 6. Governing Law. This Agreement shall be construed in accordance with and governed by the law of the State of New York.

SECTION 7. <u>Recordation</u>. The Pledgor authorizes and requests that the Commissioner for Trademarks record this Agreement with the U.S. Patent and Trademark Office.

SECTION 8. <u>Administrative Agent</u>. Cantor Fitzgerald Securities is entering into this Agreement solely in its capacity as Administrative Agent. The rights, privileges and immunities of the Administrative Agent set forth in the Credit Agreement and the Guarantee and Collateral Agreement shall be incorporated into this Agreement as though fully set forth herein.

[Remainder of this page intentionally left blank]

TRADEMARK
REEL: 006478 FRAME: 0180

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first above written.

AEGERION PHARMACEUTICALS, INC., as Pledgor

By:

Name: Barbara Chan Title: President

[Signature Page to Trademark Security Agreement]

TRADEMARK

REEL: 006478 FRAME: 0181

CANTOR FITZGERALD SECURITIES, as Administrative Agent

By:

James Buccola

Title: Head of Fixed Income

TRADEMARK COLLATERAL

Schedule I to the Trademark Security Agreement

							(STYLIZED)	
6/14/2011	3/29/2011	10/27/2010	Registered	3,977,343	85/162,494	SU	AEGERION PHARMACEUTICALS	Aegerion Pharmaceuticals, Inc.
9/25/2007	1/23/2007	6/12/2007	Registered	3,300,046	78/906,083	US	AEGERION	Aegerion Pharmaceuticals, Inc.
1/16/2018	3/21/2017	6/15/2016	Registered	5,381,517	87/072,521	SN	NOVELION THERAPEUTICS (LOGO)	Aegerion Pharmaceuticals, Inc.
1/16/2018	4/25/2017	5/19/2016	Registered	5,381,456	87/043,469	US	NOVELION THERAPEUTICS	Aegerion Pharmaceuticals, Inc.
7/4/2017	9/20/2016	10/13/2015	Registered	5,237,690	86/786,368	US	BYMYSIDE LOGO	Aegerion Pharmaceuticals, Inc.
7/4/2017	9/20/2016	10/13/2015	Registered	5,237,691	86/786,387	US	BYMYSIDE	Aegerion Pharmaceuticals, Inc.
9/16/2014	1/14/2014	8/21/2013	Registered	4,607,022	86/043,958	US	MYALEPT LOGO	Aegerion Pharmaceuticals, Inc.
8/19/2014	5/15/2012	12/1/2011	Registered	4,589,120	85/484,675	US	MYALEPT	Aegerion Pharmaceuticals, Inc.
8/29/2017	9/15/2015	3/28/2014	Registered	5,276,666	86/235,722	US	LOWER	Aegerion Pharmaceuticals, Inc.
4/8/2014		2/22/2013	Registered	4,512,713	85/981,114	US	JUXTAPID LOGO	Aegerion Pharmaceuticals, Inc.
4/1/2014		12/14/2012	Registered	4,508,190	85/980,934	SN	DIAVLYNI	Aegerion Pharmaceuticals, Inc.
Registration Date	Publication Date	Filing Date	Status	Registration No.	Application No.	Jurisdiction	Mark	Owner/ Applicant

TRADEMARK **REEL: 006478 FRAME: 0183**

RECORDED: 11/08/2018